Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation

Details for Australian Patent Application No. 2005210248 (hide)

Owner AstraZeneca AB

Inventors Green, Clive; Andrews, David Michael; Finlay, Maurice Raymond Verschoyle

Agent Davies Collison Cave

Pub. Number AU-A-2005210248

PCT Pub. Number WO2005/075461

Priority 0411998.8 28.05.04 GB; 0402277.8 03.02.04 GB

Filing date 31 January 2005

Wipo publication date 18 August 2005

International Classifications

C07D 403/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 403/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

Event Publications

10 August 2006 PCT application entered the National Phase

  PCT publication WO2005/075461 Priority application(s): WO2005/075461

12 October 2006 Amendment Made

  The nature of the amendment is: Amend the invention title to read Imidazlo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation

27 August 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005210254-Pyridinyl - or pyrimidinyl thiazoles with protein kinase inhibiting activity

2005210236-Stable amorphous forms of montelukast sodium